Suppr超能文献

抗甲状腺药物治疗的格雷夫斯甲亢患者中甲状腺素无效

Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.

作者信息

McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A

机构信息

Endocrine Clinic, Royal Infirmary, Edinburgh, Scotland.

出版信息

N Engl J Med. 1996 Jan 25;334(4):220-4. doi: 10.1056/NEJM199601253340403.

Abstract

BACKGROUND

Antithyroid drugs are effective in patients with hyperthyroidism due to Graves' disease, but the rate of recurrence after treatment is high. In a recent Japanese study, adjunctive treatment with thyroxine (T4) was associated with a recurrence rate 20 times lower than that among patients who received only an antithyroid drug. If these results are confirmed, combined therapy with an antithyroid drug and T4 might become the treatment of choice for all patients with Graves' hyperthyroidism.

METHODS

We treated 111 patients (89 women and 22 men) who had Graves' hyperthyroidism. All patients initially received 40 mg of carbimazole daily for one month. Then one group received carbimazole alone for 17 months (52 patients), and the other group received carbimazole plus T4 for 17 months and T4 alone for 18 months (59 patients). In the carbimazole group, the dose was adjusted after one month to maintain a normal serum thyrotropin concentration. In the carbimazole-T4 group, the dose of carbimazole was not changed, but 100 micrograms of T4 per day was added to the regimen and the dose was adjusted to maintain an undetectable serum thyrotropin concentration (< 0.04 microU per milliliter).

RESULTS

At the time of our analysis, 53 of the 111 patients had completed at least 3 months of follow-up (median, 12 months) after carbimazole was withdrawn. Hyperthyroidism recurred in eight patients in each group after a mean (+/- SD) of 6 +/- 4 months in the carbimazole group and 7 +/- 4 months in the carbimazole-T4 group. There was no difference between the recurrence rates in the two groups, despite the fact that serum thyrotropin concentrations were undetectable in 73 percent of patients in the carbimazole-T4 group on at least 75 percent of their visits.

CONCLUSIONS

The administration of T4 to patients with Graves' disease during carbimazole treatment and after its withdrawal neither delays nor prevents the recurrence of hyperthyroidism.

摘要

背景

抗甲状腺药物对格雷夫斯病所致甲状腺功能亢进患者有效,但治疗后复发率较高。在日本最近的一项研究中,甲状腺素(T4)辅助治疗的复发率比仅接受抗甲状腺药物治疗的患者低20倍。如果这些结果得到证实,抗甲状腺药物与T4联合治疗可能会成为所有格雷夫斯病甲亢患者的首选治疗方法。

方法

我们治疗了111例格雷夫斯病甲亢患者(89例女性和22例男性)。所有患者最初每日服用40 mg卡比马唑,持续1个月。然后一组仅接受卡比马唑治疗17个月(52例患者),另一组接受卡比马唑加T4治疗17个月,之后单独使用T4治疗18个月(59例患者)。在卡比马唑组,1个月后调整剂量以维持血清促甲状腺素浓度正常。在卡比马唑 - T4组,卡比马唑剂量不变,但每天添加100微克T4,并调整剂量以维持血清促甲状腺素浓度检测不到(<0.04微单位/毫升)。

结果

在我们分析时,111例患者中有53例在停用卡比马唑后完成了至少3个月的随访(中位数为12个月)。卡比马唑组平均(±标准差)6±4个月后,两组各有8例患者甲亢复发,卡比马唑 - T4组为7±4个月。两组的复发率没有差异,尽管卡比马唑 - T4组73%的患者在至少75%的就诊中血清促甲状腺素浓度检测不到。

结论

在卡比马唑治疗期间及停药后给予格雷夫斯病患者T4,既不会延迟也不能预防甲亢复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验